ClinicalTrials.gg
CompletedNCT03650543Updated Aug 28, 2018

Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication

A Phase 4 interventional study of amoxicillin clarithromycin omeprazole 1 and amoxicillin clarithromycin omeprazole 2 in CYP2C19 Polymorphism, H.Pylori Infection and Therapy, sponsored by Javeriana University. Completed. Open to participants aged 19 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-28.

Sponsored by Javeriana University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 years 10 months after the study started (first participant enrolled Sep 2012, registered Aug 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Study summary

Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, thus alternatives must be sought to improve eradication. Aim: To determine CYP2C19 genetic polymorphism effect on H. pylori eradication.

Methods: A randomized single blinded clinical trial including 133 patients was carried-out. H. pylori infection was confirmed by histology and microbiological test. Antibiotic susceptibility to amoxicillin and clarithromycin was performed to avoid confusion bias in analysis results. CYP2C19 polymorphism "asterisk" *1, "asterisk"*2 and "asterisk" *3 was analyzed by Real time PCR (Roche ®), and nested PCR for CYP2C19 "asterisk" *17 polymorphism. Participants were randomized into two groups for different H. pylori therapies, one with standard omeprazole doses and another with omeprazole doses depending on CYP2C19 polymorphism. H. pylori eradicating was verified by stool antigen testing (Meridian ®). The general results was analysis by statistical computer program and the effectiveness of each therapy was analyzed by intention to treat (ITT) and by protocol (PP).

The study allowed to know the prevalence of the main polymorphisms of CYP2C19 in Bogotá-Colombia, also allowed to know the effectivenesses of the two therapies evaluated for H. pylori infection. Additionally, the importance of personalized medicine in H. pylori eradication therapy was known.

Read the detailed description

Introduction:

H. pylori has been declared and ratified as carcinogen I by the World health organization (WHO) International agency for research on cancer (IARC). Globally first line therapy eradication treatment recommended for H. pylori, combines a proton-pump inhibitor (PPI) with two antibiotics (amoxicillin and clarithromycin or metronidazole). However, today effectiveness of this therapy is less than 75% "percentage", due mainly to H. pylori antibiotic resistance. Other factors involved in therapeutic failure are treatment adherence and host genetic factors that may affect medication pharmacokinetics, specifically PPI pharmacokinetics PPI play an essential role in eradication therapies, it suppresses deeply acid secretion, thus increasing hydrogen ion potential (pH) above 6.0. This allows H. pylori to replicate more actively than when stomach pH is less than 6.0, therefore improves antibiotic activity promoting greater antimicrobial agent stability and antibiotic concentration in stomach. PPIs action depends on its metabolism by cytochrome P450 (CYP) enzymes.Recent studies have showed that CYP2C19 genotype can affect PPIs ability to suppress acid secretion in the stomach, as has been observed for omeprazole. Omeprazole is metabolized by CYP2C19 (90%"percentage") and by CYP3A4 (10%"percentage"). CYP2C19 gene has 21 polymorphisms, three of which play an important role in PPIs metabolism. Thus, depending on polymorphism they are designated as early metabolizers (EM) ("asterisk"*1/"asterisk"*1), intermediate metabolizers (IM) ("asterisk"*1/"asterisk"*X) and poor metabolizers (PM) ("asterisk"*X/"asterisk"*X). Where "asterisk"*1 allele is the wild type allele ("Wild type") and "asterisk"*X correspond to mutated allele. Patients with genotype CYP2C19 "asterisk"*1/"asterisk"*2 o"asterisk" *1/"asterisk"*3 are IM and those with genotype CYP2C19 "asterisk"*2/"asterisk"*2 or CYP2C19 "asterisk"*3/"asterisk"*3 are PM. The presence of CYP2C19 "asterisk"*2 and CYP2C19 "asterisk"*3 polymorphisms predict the individual metabolizer phenotype. In 2006 the CYP2C19"asterisk"*17 allele was found, whose function is clinically important because heterozygotes, with CYP2C19"asterisk"*1/"asterisk"*17 forms are simply considered ultra-fast metabolizers by other authors. The clinical implication of this latter polymorphism relies on the following: if PPIs are quickly metabolized, standard PPIs dose fails to adequately suppress acid secretion, and H. pylori eradication therapy will be less effective if the microorganism is sensitive to antibiotics. A recent work in Colombia to eradicate H. pylori, using triple therapy with clarithromycin or levofloxacin combined with amoxicillin, reported that although the organism was sensitive to these antibiotics, there was variability with the achieved eradication. These results may suggest the possibility that additional factors, different from antimicrobial resistance, can influence the treatment effectiveness in our population.

General Methods:

The aim of present was to determine CYP2C19 genetic polymorphism influence on H.pylori eradication. For this purpose a randomized single blinded clinical trial was done. It was conducted from 2012 to 2015 in Bogotá, Colombia. The study was performed in accordance with Good Clinical Practice guidelines and ethical principles of the Declaration of Helsinki. Ethics Committee of the participating institutions approved the study protocol, where all participants signed written informed consent.

After obtaining informed consent, 356 patients were invited to participate in the study. All enrolled participants underwent initial endoscopy, carried-out at the upper endoscopy service, clinical center from Bogotá, D.C., Colombia to obtain gastric biopsy for histology, microbiological and genotypic test. However, due to the strict inclusion and exclusion criteria proposed, of the 356 participants, only 133 were included in the study.

All participants in the study underwent endoscopy of upper digestive tract under aseptic conditions, with a minimum of six hours of fasting. During the endoscopy five biopsies were taken from the antrum and four biopsies from the body for histopathology, microbiology and molecular analysis. For histopathological analysis, the biopsy samples were sent to pathology in separate properly marked containers. For microbiological and molecular analyses three antral and three body of the stomach biopsies were collected and used as follows: one biopsy from antrum for rapid urease test, two biopsies (antrum and one from the body of the stomach) for H. pylori culture and susceptibility test. Culturing was carried out only when one or both additional tests were positive for H. pylori. If the culture was negative, but any other tests were positive, microorganism detection was confirmed by molecular biology analysis (ureA gene detection H. pylori). It was considered a participant was infected with H. pylori when two or more tests were positive. Another biopsy was used for DNA extraction and subsequent analysis of CYP2C19 genetic polymorphism.

Culture was performed from biopsies of participants whose rapid urease test and histology were positive, from a biopsy of antrum and body of the stomach on Brucella agar (BD) enriched with 7% "percentage" v/v horse blood, Isovitalex (BD) and Helicobacter Pylori Selective Supplement (Dent) (Oxoid). Following, the samples were incubated at 37°C with 11% "percentage"carbon dioxide (CO2) for 3 to 5 days. Antibiotic susceptibility test from pure colonies was carried-out by agar dilution (gold standard method) according to the Clinical and Laboratory Standards Institute (CLSI) to determine amoxicillin and clarithromycin minimum inhibitory concentration (MIC). In addition, CYP2C19 polymorphism "asterisk"*1,"asterisk"*2,"asterisk"*3 and "asterisk"*17 were identified for all 133 patients included in this study. For this propose DNA was obtained from gastric biopsies by DNA Isolation from Human Samples from commercial Kit (QIAGEN), and then the identification of the respective polymorphisms was done.

CYP2C19 "asterisk"*1,"asterisk"*2,"asterisk"*3 polymorphisms were determined by real-time polymerase chain reaction (RT-PCR) using Modular Assays kit for human CYP2C19"asterisk"*2 and CYP2C19"asterisk"*3 (Roche), according to manufacturer's instructions. And nested PCR and Restriction Fragment Length Polymorphism (RFLP) was done for determination of allele "asterisk"*17 according with Baldwin et al. report.

Due to the study compared two types of therapies, the 133 patients were randomized for received the treatments into two groups by a computer program. Group one or conventional group and group 2 or personalized group. Both groups received amoxicillin and clarithromycin but first group received standard doses of omeprazole and in the second group omeprazole doses was adjusting according to the CYP2C19 polymorphism of each participant.

After performing microbiological and molecular testing, the participants were allocated to a treatment regimen according to a randomized crossover sequence, provided by a computer-generated randomization list. Participants were contacted by telephone for assigned an appointment for treatment delivery according to the assigned group.

All participants were given detailed information about the adverse effects that could occur with the different medications. Verification of possible adverse effects was performed telephonically using a validated and pre-coded questionnaire that included the following symptoms: diarrhea, metallic taste, nausea, bloated feeling, loss of appetite, vomiting, abdominal pain, constipation, and rash. The intensity of each symptom was graded from zero to three: 0: absent, 3: severe, using a Likert scale. Finally H. pylori eradication was verified 8 weeks post treatment by antigen test (Meridian®). For this test, each participants was requested a stool sample. The test was carried-out according to manufacturer's indications.

For the analysis of results, a database of the participants in excel and in spss was generated. These databases included general characteristics of each participant, result of each of the microbiology tests, molecular biology. Descriptive statistics and analysis of the effectiveness of the treatments used were carried out.

02

Conditions studied

  • CYP2C19 Polymorphism
  • H.Pylori Infection
  • Therapy
03

In context

Lead sponsor

Javeriana University is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with functional dyspepsia or peptic ulcers
  • Subjects between the ages of 19 and 70 years old
  • Subjects who were referred for upper endoscopy, and had not received previous H. pylori eradication treatment within the last six months.
  • Subjects who had not received anti-secreting acid, bismuth or antibiotics for other diseases 15 days before the endoscopy.
  • For the study, only patients with sensitive isolates of H.pylori to amoxicillin and clarithromycin were included.

Exclusion criteria

Exclusion Criteria:

  • Patients with serious comorbidities.
  • Pregnant women.
  • Patients allergic to the medications used in this study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    amoxicillin clarithromycin omeprazole 1

    This group received triple standard therapy with standard doses of omeprazole. 20 mg "omeprazole" before breakfast and before dinner. 500 mg "clarithromycin" after breakfast and after dinner and 1 g "amoxicillin" after breakfast and after dinner for 10 days.

    Drug: amoxicillin clarithromycin omeprazole 1

  • Experimental
    amoxicillin clarithromycin omeprazole 2

    This group received triple standard therapy, using 500 mg "clarithromycin" after breakfast and after dinner and 1 g "amoxicillin" after breakfast and after dinner for 10 days in addition with "omeprazole" but "omeprazole" doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 \*1/\*1 genotype (Early and ultrarapid Metabolizer): 40mg "omeprazole" before breakfast and before dinner. b) Patients with CYP2C19 \*1/\*2 or \*1/\*3 genotype (Intermediate Metabolizer): 20mg "omeprazole" before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 \*2/\*2 (Poor Metabolizer): 20mg "omeprazole" before breakfast and 20 mg before dinner.

    Drug: amoxicillin clarithromycin omeprazole 2

Interventions

  • Drugamoxicillin clarithromycin omeprazole 1

    Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.

    Also known as: Conventional therapy, Group 1

  • Drugamoxicillin clarithromycin omeprazole 2

    The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.

    Also known as: Personalized therapy, Group 2

06

What researchers measure

Primary outcomes

  1. Effectiveness of each therapy by protocol (PP)

    Percentage

    Time frame: through study completion an average of 3 years

Secondary outcomes

  1. Effectiveness of each therapy by intention to treat (ITT)

    Percentage

    Time frame: through study completion an average of 3 years

Other outcomes

  1. Gender

    percentage of male and female

    Time frame: through study completion an average of 3 years

  2. Weight

    Kilograms

    Time frame: through study completion an average of 3 years

  3. Height

    centimeters

    Time frame: through study completion an average of 3 years

  4. Body mass index

    kg/m\^2

    Time frame: through study completion an average of 3 years

  5. Prevalence of CYP2C19 polymorphism

    Percentage

    Time frame: through study completion an average of 3 years

  6. Adverse effects in each therapy

    Percentage

    Time frame: through study completion an average of 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31. doi: 10.1038/ncpgasthep1138. Epub 2008 Apr 29. PubMed 18446147 ↗
  • Sapone A, Vaira D, Trespidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol. 2003 May;98(5):1010-5. doi: 10.1111/j.1572-0241.2003.07427.x. PubMed 12809821 ↗
  • Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Ikuma M, Ishizaki T, Hishida A. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter. 2007 Aug;12(4):317-23. doi: 10.1111/j.1523-5378.2007.00508.x. PubMed 17669104 ↗
  • Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. Gastroenterol Clin North Am. 2010 Sep;39(3):465-80. doi: 10.1016/j.gtc.2010.08.007. PubMed 20951912 ↗
  • Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut. 1998 Jul;43 Suppl 1(Suppl 1):S56-60. doi: 10.1136/gut.43.2008.s56. PubMed 9764042 ↗
  • Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005 Jun;20(3):153-67. doi: 10.2133/dmpk.20.153. PubMed 15988117 ↗
  • Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res. 2008 Jun;127(6):521-30. PubMed 18765869 ↗
  • Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010 Mar;69(3):222-30. doi: 10.1111/j.1365-2125.2009.03578.x. PubMed 20233192 ↗
  • Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics. 2007 Sep;8(9):1199-210. doi: 10.2217/14622416.8.9.1199. PubMed 17924835 ↗
  • Isaza C, Henao J, Martinez JH, Sepulveda Arias JC, Beltran L. Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. BMC Clin Pharmacol. 2007 Jul 11;7:6. doi: 10.1186/1472-6904-7-6. PubMed 17623107 ↗
  • Arevalo-Galvis A, Trespalacios-Rangell AA, Otero W, Mercado-Reyes MM, Poutou-Pinales RA. Prevalence of cagA, vacA, babA2 and iceA genes in H. pylori strains isolated from Colombian patients with functional dyspepsia. Pol J Microbiol. 2012;61(1):33-40. PubMed 22708344 ↗
  • Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol. 2008 May;65(5):767-74. doi: 10.1111/j.1365-2125.2008.03104.x. Epub 2008 Feb 20. PubMed 18294333 ↗
  • Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013 Apr 30;8(4):e62162. doi: 10.1371/journal.pone.0062162. Print 2013. PubMed 23646118 ↗
  • Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014 Jun 7;20(21):6400-11. doi: 10.3748/wjg.v20.i21.6400. PubMed 24914361 ↗
  • Arevalo-Galvis A, Otero-Regino WA, Ovalle-Celis GN, Rodriguez-Gomez ER, Trespalacios-Rangel AA. Prevalence of CYP2C19 polymorphism in Bogota, Colombia: The first report of allele *17. PLoS One. 2021 Jan 27;16(1):e0245401. doi: 10.1371/journal.pone.0245401. eCollection 2021. PubMed 33503046 ↗
  • Arevalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. Helicobacter. 2019 Jun;24(3):e12574. doi: 10.1111/hel.12574. Epub 2019 Mar 11. PubMed 30859680 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2012 to primary completion in Aug 2015, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2018
First posted
Aug 28, 2018
StartActual
Sep 10, 2012
Primary completionActual
Aug 8, 2015
CompletionActual
Aug 8, 2015
Last update
Aug 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03650543
Lead sponsor
Javeriana University
Collaborators
Universidad Nacional de Colombia
Responsible party
Azucena Arévalo Galvis, MSc (Bacteriologist, Javeriana University) — Principal investigator
First posted
Aug 28, 2018
Start date
Sep 10, 2012
Primary completion
Aug 8, 2015
Completion
Aug 8, 2015
Last update
Aug 28, 2018

Study contacts

Alba Alicia Trespalacios Rangel, Ph.D
principal investigator · Pontificia Universidad Javeriana

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion